

Nano-drug-EMEA Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/NCDF4CD2AA58EN.html

Date: May 2018

Pages: 150

Price: US\$ 3,480.00 (Single User License)

ID: NCDF4CD2AA58EN

Abstracts

Report Summary

Nano-drug-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Nano-drug industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Nano-drug 2013-2017, and development forecast 2018-2023

Main market players of Nano-drug in EMEA, with company and product introduction, position in the Nano-drug market

Market status and development trend of Nano-drug by types and applications Cost and profit status of Nano-drug, and marketing status Market growth drivers and challenges

The report segments the EMEA Nano-drug market as:

EMEA Nano-drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Nano-drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):



Liposomes

Polymeric Micelles
Solid lipid Nanoparticles
Microemulsion and Nanoemulsion

Nanosuspension

EMEA Nano-drug Market: Application Segment Analysis (Consumption Volume and

Market Share 2013-2023; Downstream Customers and Market Analysis)

Cancer and Tumors

Autoimmune Disorders

EMEA Nano-drug Market: Players Segment Analysis (Company and Product introduction, Nano-drug Sales Volume, Revenue, Price and Gross Margin):

Merck

Pfizer

Novartis

Abbott

GlaxoSmithKline

Roche

Sanofi

Eli Lilly

Astrazeneca

Johnson & Johnson

Celgene

Novavax

Stryker

Gilead Sciences

OSI Pharmaceuticals

Kadmon Pharmaceuticals

Samyang Biopharm

Mitsubishi Pharma

Kaken Pharmaceutical

Selecta Biosciences

Par Pharmaceutical

Cerulean Pharma

Navidea Biopharmaceuticals

Lummy

In a word, the report provides detailed statistics and analysis on the state of the



industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF NANO-DRUG

- 1.1 Definition of Nano-drug in This Report
- 1.2 Commercial Types of Nano-drug
 - 1.2.1 Liposomes
 - 1.2.2 Polymeric Micelles
 - 1.2.3 Solid lipid Nanoparticles
 - 1.2.4 Microemulsion and Nanoemulsion
 - 1.2.5 Nanosuspension
- 1.3 Downstream Application of Nano-drug
 - 1.3.1 Cancer and Tumors
- 1.3.2 Autoimmune Disorders
- 1.4 Development History of Nano-drug
- 1.5 Market Status and Trend of Nano-drug 2013-2023
 - 1.5.1 EMEA Nano-drug Market Status and Trend 2013-2023
 - 1.5.2 Regional Nano-drug Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Nano-drug in EMEA 2013-2017
- 2.2 Consumption Market of Nano-drug in EMEA by Regions
 - 2.2.1 Consumption Volume of Nano-drug in EMEA by Regions
 - 2.2.2 Revenue of Nano-drug in EMEA by Regions
- 2.3 Market Analysis of Nano-drug in EMEA by Regions
 - 2.3.1 Market Analysis of Nano-drug in Europe 2013-2017
 - 2.3.2 Market Analysis of Nano-drug in Middle East 2013-2017
 - 2.3.3 Market Analysis of Nano-drug in Africa 2013-2017
- 2.4 Market Development Forecast of Nano-drug in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Nano-drug in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Nano-drug by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
 - 3.1.1 Consumption Volume of Nano-drug in EMEA by Types
 - 3.1.2 Revenue of Nano-drug in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries



- 3.2.1 Market Status by Types in Europe
- 3.2.2 Market Status by Types in Middle East
- 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Nano-drug in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Nano-drug in EMEA by Downstream Industry
- 4.2 Demand Volume of Nano-drug by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Nano-drug by Downstream Industry in Europe
- 4.2.2 Demand Volume of Nano-drug by Downstream Industry in Middle East
- 4.2.3 Demand Volume of Nano-drug by Downstream Industry in Africa
- 4.3 Market Forecast of Nano-drug in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF NANO-DRUG

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Nano-drug Downstream Industry Situation and Trend Overview

CHAPTER 6 NANO-DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Nano-drug in EMEA by Major Players
- 6.2 Revenue of Nano-drug in EMEA by Major Players
- 6.3 Basic Information of Nano-drug by Major Players
 - 6.3.1 Headquarters Location and Established Time of Nano-drug Major Players
 - 6.3.2 Employees and Revenue Level of Nano-drug Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 NANO-DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Merck
 - 7.1.1 Company profile
 - 7.1.2 Representative Nano-drug Product



- 7.1.3 Nano-drug Sales, Revenue, Price and Gross Margin of Merck
- 7.2 Pfizer
 - 7.2.1 Company profile
 - 7.2.2 Representative Nano-drug Product
 - 7.2.3 Nano-drug Sales, Revenue, Price and Gross Margin of Pfizer
- 7.3 Novartis
 - 7.3.1 Company profile
 - 7.3.2 Representative Nano-drug Product
 - 7.3.3 Nano-drug Sales, Revenue, Price and Gross Margin of Novartis
- 7.4 Abbott
 - 7.4.1 Company profile
 - 7.4.2 Representative Nano-drug Product
 - 7.4.3 Nano-drug Sales, Revenue, Price and Gross Margin of Abbott
- 7.5 GlaxoSmithKline
 - 7.5.1 Company profile
 - 7.5.2 Representative Nano-drug Product
 - 7.5.3 Nano-drug Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
- 7.6 Roche
 - 7.6.1 Company profile
 - 7.6.2 Representative Nano-drug Product
 - 7.6.3 Nano-drug Sales, Revenue, Price and Gross Margin of Roche
- 7.7 Sanofi
 - 7.7.1 Company profile
 - 7.7.2 Representative Nano-drug Product
 - 7.7.3 Nano-drug Sales, Revenue, Price and Gross Margin of Sanofi
- 7.8 Eli Lilly
 - 7.8.1 Company profile
 - 7.8.2 Representative Nano-drug Product
 - 7.8.3 Nano-drug Sales, Revenue, Price and Gross Margin of Eli Lilly
- 7.9 Astrazeneca
 - 7.9.1 Company profile
 - 7.9.2 Representative Nano-drug Product
 - 7.9.3 Nano-drug Sales, Revenue, Price and Gross Margin of Astrazeneca
- 7.10 Johnson & Johnson
 - 7.10.1 Company profile
 - 7.10.2 Representative Nano-drug Product
 - 7.10.3 Nano-drug Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.11 Celgene
- 7.11.1 Company profile



- 7.11.2 Representative Nano-drug Product
- 7.11.3 Nano-drug Sales, Revenue, Price and Gross Margin of Celgene
- 7.12 Novavax
 - 7.12.1 Company profile
 - 7.12.2 Representative Nano-drug Product
 - 7.12.3 Nano-drug Sales, Revenue, Price and Gross Margin of Novavax
- 7.13 Stryker
 - 7.13.1 Company profile
 - 7.13.2 Representative Nano-drug Product
 - 7.13.3 Nano-drug Sales, Revenue, Price and Gross Margin of Stryker
- 7.14 Gilead Sciences
 - 7.14.1 Company profile
 - 7.14.2 Representative Nano-drug Product
 - 7.14.3 Nano-drug Sales, Revenue, Price and Gross Margin of Gilead Sciences
- 7.15 OSI Pharmaceuticals
 - 7.15.1 Company profile
 - 7.15.2 Representative Nano-drug Product
 - 7.15.3 Nano-drug Sales, Revenue, Price and Gross Margin of OSI Pharmaceuticals
- 7.16 Kadmon Pharmaceuticals
- 7.17 Samyang Biopharm
- 7.18 Mitsubishi Pharma
- 7.19 Kaken Pharmaceutical
- 7.20 Selecta Biosciences
- 7.21 Par Pharmaceutical
- 7.22 Cerulean Pharma
- 7.23 Navidea Biopharmaceuticals
- **7.24 Lummy**

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NANO-DRUG

- 8.1 Industry Chain of Nano-drug
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF NANO-DRUG

- 9.1 Cost Structure Analysis of Nano-drug
- 9.2 Raw Materials Cost Analysis of Nano-drug



- 9.3 Labor Cost Analysis of Nano-drug
- 9.4 Manufacturing Expenses Analysis of Nano-drug

CHAPTER 10 MARKETING STATUS ANALYSIS OF NANO-DRUG

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
- 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Nano-drug-EMEA Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/NCDF4CD2AA58EN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/NCDF4CD2AA58EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970